Deborah Leone Buys Shares of Organon & Co. (OGN)

Deborah Leone purchased 17,857 shares of Organon & Co. at $13.44 each.

Written by EarningsIQ · Published Jun 16, 2026, 2:02 AM EDT · Updated Jun 16, 2026, 2:01 PM EDT

Key Points

Deborah Leone bought 17,857 shares of Organon & Co. at $13.44 per share, totaling $239,998.08, on June 12, 2026.
Organon & Co. has a market cap of about $3.53 billion and a P/E ratio of 14.45, with its stock trading near its 52-week high of $13.49.
Analyst ratings for Organon & Co. vary, with BNP Paribas recently downgrading the stock to hold with a $14.00 target.

On June 12, 2026, Deborah Leone purchased 17,857 shares of Organon & Co. (NYSE: OGN) at a price of $13.44 per share. This transaction was valued at approximately $239,998.08 and was not part of a pre-planned trading program.

Insider Buying and Selling at Organon & Co.

Deborah Leone wasn't the only insider buying shares of Organon & Co. on June 12, 2026. Shalini Sharp, Philip Ozuah, Ramona Sequeira, Cynthia Patton, and Rochelle Lazarus each bought 17,857 shares at the same price of $13.44 per share. These purchases were also not part of any pre-planned trading programs.

Other Institutional Activity in Organon & Co.

BlackRock, Inc. increased its holdings by 751,009 shares, ending with a total of 31,717,028 shares valued at about $189.98 million. Vanguard Portfolio Management LLC added 21,846,036 shares, bringing its total to the same number, valued at approximately $130.86 million. Vanguard Capital Management LLC also acquired 11,737,018 shares, resulting in a total holding worth $70.30 million. Meanwhile, State Street Corp boosted its stake by 359,013 shares to 9,956,774 shares, valued at $59.64 million. LSV Asset Management, however, reduced its position by 212,699 shares, holding 7,259,730 shares worth $43.49 million.

Organon & Co. Stock Snapshot

Shares of Organon & Co. traded at $13.44 on the NYSE, close to their 52-week high of $13.49. The company has a market capitalization of about $3.53 billion and a P/E ratio of 14.45. Organon & Co. shows a forward P/E of 3.67 and a beta of 1.54, indicating potential volatility. The stock's 50-day moving average is $11.88, while the 200-day moving average is $9.04. The company maintains a current ratio of 1.97 and a quick ratio of 1.0, with a high debt-to-equity ratio of 948.95.

Recent Earnings

Organon & Co. reported revenue of approximately $6.16 billion, though this marked a slight decline of 3.5% from the previous period. The company's earnings per share stood at $0.93, with a net margin of 3.99% and a return on equity of 34.05%. The next earnings report is scheduled for August 4, 2026.

Dividend

Organon & Co. offers an annual dividend rate of $0.08, yielding 0.6% with a payout ratio of 8.6%.

Analysts Set New Price Targets

On April 29, 2026, BNP Paribas downgraded Organon & Co. to a hold rating with a price target of $14.00. Piper Sandler upgraded the stock to hold on April 28, 2026, also with a $14.00 target. Barclays maintained a sell rating with a target of $8.00 on February 24, 2026. The consensus among analysts is a hold, with a mean price target of $11.25 based on four opinions.

About Organon & Co.

Organon & Co. is a healthcare company based in Jersey City, New Jersey, specializing in women's health solutions. The company offers a range of prescription therapies and medical devices across various regions, including the U.S., Europe, and Asia. Led by CEO Joseph T. Morrissey Jr., Organon employs around 10,000 people and operates in the drug manufacturing sector.

Bottom Line

Deborah Leone's purchase of Organon & Co. shares highlights insider confidence in the company. With a diverse portfolio and a significant market presence, Organon & Co. is an important player in the healthcare sector. Investors often track such insider activity for potential insights, though it's important to remember that these transactions are disclosed after the fact and may not indicate future performance.